Log in

Term Sheets and Valuations

  • 03 Mar 2015
  • 7:00 PM - 9:45 PM
  • Constant Contact, 1601 Trapelo Rd., 1st Floor Great Room, Waltham (Exit 28, I-95/Route 128)

Meeting Presentations:


Come listen to our panel of founders and executives talk about their experiences negotiating a term sheet with investors and/or strategic partners and how they established a valuation for their company. Learn about what terms impact founders’ managerial control of investments and operating decisions. What value does your company contribute to a potential investor’s portfolio? These and other exciting questions will be addressed by our speakers using real examples. For your individual concerns, a networking session will precede the meeting and a question and answer session will follow the panelists’ presentations.




Jules Fried is a principal in Fried, Bahl & Associates, a growth advisory firm specializing in emerging and middle market companies.  He is also currently forming a CEO peer advisory group at the invitation of Vistage International, the world’s leading CEO organization.  He is a serial entrepreneur, attorney, venture mentor, and angel investor. He founded a two time Inc. 500 company that grew to $47 million in revenue, is co-founder and director of First Commons Bank, one of the fastest growing banks in the country, and started a health care law firm that was eventually merged into a major national firm.  His functional expertise spans business strategy, capital raising, talent acquisition, strategic alliances, marketing and sales, intellectual property and product planning and management. He speaks frequently on capital raising and other issues facing early stage companies.  He holds an AB from Princeton University and JD, cum laude, from the University of Michigan Law School.


Thomas Farb founded and is the President of Estabrook Ventures, LLC, http://estabrookventures.com, providing interim management services, business plan development and angel investments to numerous medical and technology companies.  As part of Estabrook Ventures, Mr. Farb has had such assignments as developing the business plan for the formation of Thrive Bioscience, Inc., President of MedicaMetrix, a prostate cancer diagnostic company and as Co-founder & President of Precision Ventures, LLC, a diversified medical device development and licensing company. Currently, Mr. Farb is a Co-Founder and part-time CFO and Advisor to Brahman Industries, LLC, developer of the STATIM ("Storm, Tornado And Tsunami Interconnected Module”) Shelter System, an innovative & life saving modular concrete, floating shelter that will have significant global & social impact and save lives where previously not possible, particularly in a tsunami or other disasters. In 2012 through 2013, Mr. Farb was Co-Founder, EVP of Corporate Development & CFO of Atherio, a global IT Services & web/mobile development company with headquarters in Florida and offices in the U.S., London and India.

Perviously, Mr. Farb was Executive Director of the Trust for Science, Technology and Research, San Juan Puerto Rico and President & Chief Operating Officer of Indevus Pharmaceuticals (NASDAQ: IDEV), Lexington, MA, a $100 million revenue company developing products for and marketing pharmaceuticals and devices to urologists and endocrinologists. The company was acquired by Endo Health Solutions (NASDAQ: ENDP).


Mr. Tom Kinneman, MBA, is Vice President & COO of North Shore InnoVentures, http://nsiv.org. Mr. Kinneman is also President of the North Shore Technology Council. Formerly, he was President of the Image Polymers unit of Mitsui Chemicals, headquartered in Wilmington, MA. The company develops, manufactures, and markets resins used in toners for laser printers and copiers. Mr. Kinneman has a consistent record of new business growth and profit improvement in diverse American, European and Asian markets. He has strong strategic capabilities, broad general management background, and proven leadership with multi-functional, global teams. Particularly skilled in driving new technology introductions, establishing new businesses, and penetrating international markets, Mr. Kinneman successfully led global businesses in electronic chemicals, coating resins, and specialty pigments: He spent five years managing European paper chemicals business from the Netherlands and three years running Asian specialty chemicals business from Singapore. Mr. Kinneman holds a B.S. in chemical engineering from Cornell University and an MBA in International Business from the University of Connecticut.




Dr. Roger Frechette is Co-Founder and Principal of New England PharmAssociates, a consultancy offering on-demand executive and business advisory services to life sciences enterprises. He is also the US East Coast Ambassador for Medicon Valley Alliance, a life sciences cluster organization based in Copenhagen. Previously, he was a Co-Founder of Frontiera Therapeutics, a startup developing therapeutics for vascular leak. He is a volunteer adviser and mentor with several Boston area biotech incubators and startup mentoring programs. Previously, Dr. Frechette was Co-Founder of MaxThera, an antibacterial drug discovery company. MaxThera was sold in 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company.  Prior to starting MaxThera, Dr. Frechette was a drug discovery and life-sciences consultant following his role as Project Director at Paratek Pharmaceuticals (Boston). At Paratek he led the team that discovered PTK0796 (currently in Phase III clinical trials) with strategic partner Glaxo-Wellcome, and the pre-clinical development program that was carried out with a multinational team of consultants and contractors.  Previously, he was Associate Director of Chemistry at RiboGene (Hayward, CA), where he built the chemistry department and managed two drug discovery programs in collaboration with strategic partner Dainippon Pharmaceuticals. He began his career as a medicinal chemist at the R.W. Johnson Pharmaceutical Research Institute (J&J, Raritan, NJ). Dr. Frechette was a Post-Doctoral Fellow at Yale University, earned his PhD in Organic Chemistry from Wesleyan University and his BA in Chemistry from College of the Holy Cross